Cargando…
RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
Majority of the known breast cancer susceptibility genes have a role in DNA repair and the most important high-risk genes BRCA1 and BRCA2 are specifically involved in the homologous recombination repair (HRR) of DNA double-strand breaks. A central player in HRR is RAD51 that binds DNA at the damage...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404470/ https://www.ncbi.nlm.nih.gov/pubmed/25918678 http://dx.doi.org/10.1186/s40064-015-0880-3 |
_version_ | 1782367495347240960 |
---|---|
author | Pelttari, Liisa M Kiiski, Johanna I Ranta, Salla Vilske, Sara Blomqvist, Carl Aittomäki, Kristiina Nevanlinna, Heli |
author_facet | Pelttari, Liisa M Kiiski, Johanna I Ranta, Salla Vilske, Sara Blomqvist, Carl Aittomäki, Kristiina Nevanlinna, Heli |
author_sort | Pelttari, Liisa M |
collection | PubMed |
description | Majority of the known breast cancer susceptibility genes have a role in DNA repair and the most important high-risk genes BRCA1 and BRCA2 are specifically involved in the homologous recombination repair (HRR) of DNA double-strand breaks. A central player in HRR is RAD51 that binds DNA at the damage site. The RAD51 paralogs RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3 facilitate the binding of RAD51 to DNA. While germline mutations in RAD51C and RAD51D are associated with high ovarian cancer risk and RAD51B polymorphisms with breast cancer, the contribution of RAD51, XRCC3, and XRCC2 is more unclear. To investigate the role of RAD51, XRCC3, and XRCC2 in breast cancer predisposition and to identify putative recurrent founder mutations in the Finnish population where such mutations have been observed in most of the currently known susceptibility genes, we screened 182 familial Finnish breast or ovarian cancer patients for germline variation in the RAD51and XRCC3 genes and 342 patients for variation in XRCC2, with a subset of the patients selected on the basis of decreased RAD51 protein expression on tumors. We also performed haplotype analyses for 1516 breast cancer cases and 1234 controls to assess the common variation in these genes. No pathogenic mutations were detected in any of the genes and the distribution of haplotypes was similar between cases and controls. Our results suggest that RAD51, XRCC3, and XRCC2 do not substantially contribute to breast cancer predisposition in the Finnish population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40064-015-0880-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4404470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-44044702015-04-27 RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families Pelttari, Liisa M Kiiski, Johanna I Ranta, Salla Vilske, Sara Blomqvist, Carl Aittomäki, Kristiina Nevanlinna, Heli Springerplus Research Majority of the known breast cancer susceptibility genes have a role in DNA repair and the most important high-risk genes BRCA1 and BRCA2 are specifically involved in the homologous recombination repair (HRR) of DNA double-strand breaks. A central player in HRR is RAD51 that binds DNA at the damage site. The RAD51 paralogs RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3 facilitate the binding of RAD51 to DNA. While germline mutations in RAD51C and RAD51D are associated with high ovarian cancer risk and RAD51B polymorphisms with breast cancer, the contribution of RAD51, XRCC3, and XRCC2 is more unclear. To investigate the role of RAD51, XRCC3, and XRCC2 in breast cancer predisposition and to identify putative recurrent founder mutations in the Finnish population where such mutations have been observed in most of the currently known susceptibility genes, we screened 182 familial Finnish breast or ovarian cancer patients for germline variation in the RAD51and XRCC3 genes and 342 patients for variation in XRCC2, with a subset of the patients selected on the basis of decreased RAD51 protein expression on tumors. We also performed haplotype analyses for 1516 breast cancer cases and 1234 controls to assess the common variation in these genes. No pathogenic mutations were detected in any of the genes and the distribution of haplotypes was similar between cases and controls. Our results suggest that RAD51, XRCC3, and XRCC2 do not substantially contribute to breast cancer predisposition in the Finnish population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40064-015-0880-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-02-24 /pmc/articles/PMC4404470/ /pubmed/25918678 http://dx.doi.org/10.1186/s40064-015-0880-3 Text en © Pelttari et al.; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Pelttari, Liisa M Kiiski, Johanna I Ranta, Salla Vilske, Sara Blomqvist, Carl Aittomäki, Kristiina Nevanlinna, Heli RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families |
title | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families |
title_full | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families |
title_fullStr | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families |
title_full_unstemmed | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families |
title_short | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families |
title_sort | rad51, xrcc3, and xrcc2 mutation screening in finnish breast cancer families |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404470/ https://www.ncbi.nlm.nih.gov/pubmed/25918678 http://dx.doi.org/10.1186/s40064-015-0880-3 |
work_keys_str_mv | AT pelttariliisam rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies AT kiiskijohannai rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies AT rantasalla rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies AT vilskesara rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies AT blomqvistcarl rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies AT aittomakikristiina rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies AT nevanlinnaheli rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies |